Das Biswadeep, Sarkar Chayna
Department of Pharmacology, Sikkim Manipal Institute of Medical Sciences, 5th Mile, Tadong, Gangtok, Sikkim, India.
Vascul Pharmacol. 2007 Oct;47(4):248-56. doi: 10.1016/j.vph.2007.06.008. Epub 2007 Jul 4.
Provocation of fatal cardiac arrhythmias has limited the use of inotropic agents as heart failure therapy. Levosimendan (LEV) is a new inodilator, whose mechanism of action includes calcium sensitization of contractile proteins and the opening of ATP-dependent potassium channels.
The aim of this investigation was to test whether the administration of LEV has cardioprotective and antiarrhythmic effects against ischemia and reperfusion injury in a manner similar to ischemic preconditioning (IPC) in a well-standardized model of reperfusion arrhythmias in anesthetized adult male rabbits (n=122) subjected to 30 min occlusion of the left coronary artery followed by 120 min of reperfusion.
Pretreatment with either 1 cycle of IPC, LEV (0.1 micromol/kg, i.v.), or IPC+LEV prior to the period of coronary occlusion offers significant infarct size reduction (21.6+/-1.6%, 22.1+/-2.2%, and 21.4+/-1.4%, respectively vs 38.7+/-3.6% in saline control group; P<0.01) and antiarrhythmic effects. IPC, LEV and IPC+LEV treatment significantly attenuated the incidence of life-threatening arrhythmias like sustained VT (13%, 13% and 13%, respectively vs 100% in saline control group; P<0.005) and other arrhythmias (25%, 25% and 13%, respectively vs 100% in saline control group; P<0.005), and increased the number of surviving animals without arrhythmias. Pretreatment with 5-HD, N(omega)-nitro-L-arginine methyl ester (L-NAME, a nonspecific NOS inhibitor) and the specific iNOS inhibitor 1400 W [N-(-3-(aminomethyl)benzyl) acetamidine] abolished the beneficial effects of IPC, and LEV on reperfusion induced arrhythmias and cardioprotection suggesting that benefits have been achieved via both the selective activation of cardiomyocyte mitochondrial K(ATP) channels and NO. One cycle of IPC and LEV pretreatment significantly preserved the level of ATP in the 30 min ischemic heart and 120 min reperfused heart.
The present study demonstrates similarities between acute LEV treatment and IPC of the rabbit myocardium in terms of survival, cardioprotection, antiarrhythmic activity, and metabolic status.
诱发致命性心律失常限制了正性肌力药物作为心力衰竭治疗药物的应用。左西孟旦(LEV)是一种新型的血管扩张性正性肌力药物,其作用机制包括收缩蛋白的钙增敏作用和ATP依赖性钾通道的开放。
本研究旨在检测在标准化的成年雄性麻醉兔(n = 122)再灌注心律失常模型中,左西孟旦的给药是否能以类似于缺血预处理(IPC)的方式对缺血再灌注损伤产生心脏保护和抗心律失常作用。该模型先对左冠状动脉进行30分钟的闭塞,随后进行120分钟的再灌注。
在冠状动脉闭塞前,用1个周期的IPC、左西孟旦(0.1微摩尔/千克,静脉注射)或IPC + 左西孟旦预处理,均可显著减小梗死面积(分别为21.6±1.6%、22.1±2.2%和21.4±1.4%,而生理盐水对照组为38.7±3.6%;P < 0.01)并具有抗心律失常作用。IPC、左西孟旦和IPC + 左西孟旦治疗显著降低了危及生命的心律失常如持续性室性心动过速(分别为13%、13%和13%,而生理盐水对照组为100%;P < 0.005)和其他心律失常(分别为25%、25%和13%,而生理盐水对照组为100%;P < 0.005)的发生率,并增加了无心律失常存活动物的数量。用5 - HD、N(ω)-硝基 - L -精氨酸甲酯(L - NAME,一种非特异性一氧化氮合酶抑制剂)和特异性诱导型一氧化氮合酶抑制剂1400W [N - (-3 - (氨基甲基)苄基)乙脒]预处理可消除IPC和左西孟旦对再灌注诱导的心律失常和心脏保护的有益作用,这表明其有益作用是通过心肌细胞线粒体ATP敏感性钾通道的选择性激活和一氧化氮实现的。1个周期的IPC和左西孟旦预处理可显著维持30分钟缺血心脏和120分钟再灌注心脏中的ATP水平。
本研究表明,在存活、心脏保护、抗心律失常活性和代谢状态方面,急性左西孟旦治疗与兔心肌的IPC具有相似性。